DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
300 River Place, Suite 5900 Detroit, MI 48207 (313) 393-8100 Fax:(313)393-8139	4/20/2026-4/24/2026 FEI NUMBER 3043365433

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Brian C. DeBeaubien, M.D., Clinical Investigator

FIRM NAME	STREET ADDRESS
Brian C. DeBeaubien, M.D.	5400 Mackinaw Road, Covenant Healthcare
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Saginaw, MI 48604	Clinical Investigator

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:
For Study Protocol JPS-0301

OBSERVATION 1

An investigation was not conducted in accordance with the investigational plan.

Specifically, Protocol Section 8.1 requires that (b)(4) at Stage (b)(4) and Stage (b)(4) surgery. However, my review of 11 subject records found that these required cultures were not performed for 8 subjects.

Subject ID	Treatment Assignment	Initial Date of Assigned Treatment	Samples (b)(4) (b)(4) at these Surgery Stages
(b) (6), (b) (7)(C)	(b)(4)	(b) (6), (b) (7)(C)	Stages (b)(4)
			Stage (b)(4)
			Stages (b)(4)
			Stages (b)(4)
			Stages (b)(4)
			Stage (b)(4)
			Stages (b)(4)
			Stage (b)(

SEE REVERSE OF THIS PAGE

EMPLOYEE(S) SIGNATURE
Stephen O Agyemang, Investigator

X Stephen O Agyemang Investigator Signed By: STEPHEN O. AGYEMANG -S Date Signed: 04-24-2026 16:24:07

DATE ISSUED
4/24/2026

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
300 River Place, Suite 5900 Detroit, MI 48207 (313) 393-8100 Fax:(313)393-8139	4/20/2026-4/24/2026
	FEI NUMBER 3043365433

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Brian C. DeBeaubien, M.D., Clinical Investigator

FIRM NAME	STREET ADDRESS
Brian C. DeBeaubien, M.D.	5400 Mackinaw Road, Covenant Healthcare
CITY, STATE, ZIP CODE, COUNTRY Saginaw, MI 48604	TYPE ESTABLISHMENT INSPECTED Clinical Investigator

SEE REVERSE OF THIS PAGE

EMPLOYEE(S) SIGNATURE
Stephen O Agyemang, Investigator

X Stephen O Agyemang
Investigator
Signed By: STEPHEN O. AGYEMANG -S
Date Signed: 04-24-2026 16:24:07

DATE ISSUED
4/24/2026

The observations of objectionable conditions and practices listed on the front of this form are reported:

1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."